secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2025-04-03T23:59:59+00:00
Accession:  0001447028-25-000093
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus Biopharma finalizes separation agreements with ex-CMO and ex-CFO; updates Moderna trial date
--------------------------------------------------------------------------------

- CMO Karen Sims terminated without cause effective March 25, 2025; enters 30-day consulting agreement with hourly fee and extended option exercise to March 24, 2026.
- CFO David Hastings terminated without cause effective March 27, 2025; separation agreement extends option exercise to March 26, 2026.
- Patent litigation vs Moderna: District of Delaware moved trial start from September 24 to September 29, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000144702825000093/0001447028-25-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000144702825000093/abus-20250328.htm
  HTML page:      https://secwatch.observer/filing/0001447028-25-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer